Browse

Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer

Cited 15 time in Web of Science Cited 17 time in Scopus
Authors
Lee, Hyo-Pyo; Seo, Sang-Soo; Ryu, Sang-Young; Kim, Jong-Hyeok; Bang, Yung-Jue; Park, Sang-Yoon; Nam, Joo-Hyun; Kang, Soon-Beom; Lee, Kyung-Hee; Song, Yong Sang
Issue Date
2008-04-15
Publisher
Elsevier
Citation
Gynecol Oncol. 2008;109(3):359-363
Keywords
AdultAntineoplastic Agents, Phytogenic/*administration & dosageAntineoplastic Combined Chemotherapy Protocols/administration & dosageCamptothecin/administration & dosage/adverse effects/*analogs & derivativesDNA Topoisomerases, Type I/antagonists & inhibitorsDrug Administration ScheduleDrug Resistance, NeoplasmEnzyme Inhibitors/administration & dosageFemaleHumansMiddle AgedNeoplasm Recurrence, Local/*drug therapyOrganoplatinum Compounds/administration & dosageOvarian Neoplasms/*drug therapy
Abstract
BACKGROUND: To evaluate the toxicity and efficacy of a newly developed topoisomerase I inhibitor, CKD-602 in second-line therapy of ovarian cancer. METHODS: We enrolled 24 patients with recurrent ovarian cancer, of median age 54 years (range, 39-64). Eleven patients had measurable lesions on CT scan, and the other 13 had increased serum CA-125 levels. Eighteen patients had platinum-sensitive disease (minimum treatment free interval > or =6 months) and 6 had platinum-resistant disease (minimum treatment free interval <6 months). CKD-602 (0.5 mg/m(2)/day) was administered intravenously for 5 days every 3 weeks. The median number of courses per patient was 6 (range, 1 to 12). Response was evaluated by the evaluation of the size of the mass by CT scan and CA-125 response. RESULTS: The overall response rate was 45.0% (9/20), with 4 patients exhibiting partial responses and 5 patients exhibiting 75% CA-125 responses in 20 evaluable patients. Of the 9 responsive patients, 8 were platinum-sensitive (8/15, 53.3%) and 1 was platinum-resistant (1/5, 20.0%). An additional 5 patients showed stable disease, whereas 6 patients exhibited progressive lesions. Of 24 patients, the most common toxicity was hematological, with grades 3 or 4 neutropenia developing in all 24 patients (100%) and in 94 cycles (71.7%). Grade 3 thrombocytopenia developed in 4 patients (16.7%) and 6 cycles (4.6%). None of the patients experienced grades 3 and 4 gastrointestinal toxicities, including nausea, vomiting, and anorexia. CONCLUSIONS: The newly developed topoisomerase I inhibitor, CKD-602, showed activity against both platinum-sensitive and -resistant ovarian cancer, with acceptable toxicity.
ISSN
1095-6859 (Electronic)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18405948

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WG6-4S80CP0-1-1&_cdi=6814&_user=168665&_orig=search&_coverDate=06%2F30%2F2008&_sk=998909996&view=c&wchp=dGLbVlz-zSkzk&md5=86a2bc37296f11b254d7bbb37aff5312&ie=/sdarticle.pdf

http://hdl.handle.net/10371/68075
DOI
https://doi.org/10.1016/j.ygyno.2007.11.023
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Obstetrics & Gynecology (산부인과전공)Journal Papers (저널논문_산부인과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse